Jun 2, 2026 – 7.00pmWashington | Nasdaq-listed online pharmacy giant Hims & Hers will retire the Australian digital wellness brands it acquired in the $1.6 billion buyout of Eucalyptus, according to chief executive Andrew Dudum, who wants a unified approach as he seeks to shake up healthcare around the world.But Australian customers hoping to benefit from the $US6 billion ($8 billion) company’s concerted push into selling controversial but popular peptides will be forced to wait as the strategy remains focused on the US market for now.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles
New Eucalyptus owner says Australia will have to wait on peptide push
Australia tightly controls peptide access, but US drug regulators have shown increasing support, meaning some websites could be selling them by the end of the year.
TL;DRAI
Hims & Hers ($6B) retires Australian brands from $1.6B Eucalyptus deal; CEO delays peptide expansion to US-only GTM. Regulatory gating in healthcare highlights compliance-first GTM: market entry deferred on regulation, not product maturity.
107 words~1 min read
